Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;11(3):261-266.
doi: 10.1111/cts.12532. Epub 2017 Dec 22.

Mechanisms of Action and Clinical Development of Elotuzumab

David Ritchie  1 , Marco Colonna  2
Affiliations
Review

Mechanisms of Action and Clinical Development of Elotuzumab

David Ritchie et al. Clin Transl Sci. 2018 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signaling lymphocytic activation molecule F7 (SLAMF7) structure and signaling mechanism. SLAMF7 is a self‐ligand that recognizes and binds to SLAMF7 on other cells (e.g., myeloma cells can bind to other myeloma cells via SLAMF7 coupling). Natural killer (NK) cell activation after SLAMF7 coupling is dependent on Ewing's sarcoma‐associated transcript 2 (EAT‐2) signaling. Ig, immunoglobulin; ITSM, immunoreceptor tyrosine‐based switch motif; SH2, Src homology 2.
Figure 2
Figure 2
Elotuzumab mechanism of action. Elotuzumab primarily acts by activating natural killer (NK) cell–mediated killing of myeloma cells via antibody‐dependent cellular cytotoxicity (A). Elotuzumab also directly activates NK cells to kill myeloma cells (B). EAT‐2, Ewing's sarcoma‐associated transcript 2; SLAMF7, signaling lymphocytic activation molecule F7. Figure from Lonial, S. et al. Expert Opin. Biol. Ther. 16, 1291–1301 (2016). Reprinted with permission from Taylor & Francis © 2016.
Figure 3
Figure 3
Kaplan–Meier curves showing progression‐free survival (PFS) in patients with relapsed or refractory multiple myeloma receiving elotuzumab plus lenalidomide and dexamethasone (“Elotuzumab”) or lenalidomide and dexamethasone (“Control”). Figure from Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621–631. ©2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Figure 4
Figure 4
Kaplan–Meier curves showing (A) progression‐free survival (PFS) and (B) overall survival (OS) in patients with relapsed or refractory multiple myeloma receiving lenalidomide (L) and/or dexamethasone (d/Dex). Reprinted with permission from Macmillan Publishers: Dimopoulos, M.A. et al. Leukemia 23, 2147–2152 (2009), ©2009.
Figure 5
Figure 5
Kaplan–Meier curves showing overall survival (OS) in patients with relapsed or refractory multiple myeloma receiving elotuzumab plus lenalidomide and dexamethasone (“Elotuzumab”) or lenalidomide and dexamethasone (“Control”). Figure from Dimopoulos, M.A. et al. Br. J. Haematol. 178, 896–905 (2017). Reprinted with permission from John Wiley & Sons ©2017.
See this image and copyright information in PMC

References

    1. Siegel, R. , Ma, J. , Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9–29 (2014). - PubMed
    1. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 3. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2016).
    1. Lonial, S. , Kaufman, J. , Laubach, J. & Richardson, P. Elotuzumab: a novel anti‐CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin. Biol. Ther. 13, 1731–1740 (2013). - PubMed
    1. Pratt, G. , Goodyear, O. & Moss, P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138, 563–579 (2007). - PubMed
    1. Lonial, S. et al Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621–631 (2015). - PubMed

MeSH terms

Substances

LinkOut - more resources